A Study of MG1111 in Healthy Children
A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children
Sponsor: Green Cross Corporation
A PHASE2/PHASE3 clinical study on Healthy Children, this trial is completed. The trial is conducted by Green Cross Corporation and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2021 — Jul 2022 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Green Cross Corporation
For direct contact, visit the study record on ClinicalTrials.gov .